文献速递心律失常心力衰竭与心肌病

一级预防植入式心律转复除颤器的临床有效性:EU-CERT-ICD对照多中心队列研究结果

Clinical effectiveness of primary prevention implantable cardioverter-defibrillators: results of the EU-CERT-ICD controlled multicentre cohort study.
PubMed 文献 · Eur Heart J · 2020-01-01

EU-CERT-ICD是一项前瞻性、研究者发起的对照队列研究,在15个欧洲国家44个中心纳入2327例缺血性心肌病或扩张型心肌病且符合指南预防性ICD植入指征的患者,比较ICD组与无ICD对照组的全因死亡率。中位随访2.4±1.1年,校正后ICD组死亡率降低27%(HR 0.731,95%CI 0.569-0.938,P=0.0140),但糖尿病和≥75岁患者未见明显获益。

要点

  • 现代ICM/DCM患者(LVEF≤35%、窄QRS)中,预防性ICD与校正后27%的死亡率降低相关。
  • 糖尿病患者和≥75岁患者可能生存获益较少,需个体化评估。
  • 研究为观察性对照设计,结果需结合随机对照试验证据解读。

核心结论

  • 在现代缺血性心肌病或扩张型心肌病(LVEF≤35%、窄QRS)患者中,一级预防性ICD治疗经校正后与27%的死亡率降低相关(HR 0.731,95%CI 0.569-0.938,P=0.0140)。

研究设计与样本

  • EU-CERT-ICD为前瞻性、研究者发起的对照队列研究,在15个欧洲国家44个中心开展,纳入2327例符合指南预防性ICD植入指征的缺血性心肌病或扩张型心肌病患者。
  • 基线记录临床特征、用药、静息及12导联动态心电图,最终2247例可分析,其中ICD组1516例、无ICD对照组731例,采用多变量模型和倾向性评分校正比较死亡率。

主要发现

  • 平均随访2.4±1.1年,共342例死亡,年化死亡率为6.3%/年(ICD组5.6%/年 vs. 对照组9.2%/年),未校正HR 0.682(95%CI 0.537-0.865,P=0.0016)。
  • 多变量死亡预测因素包括年龄、左心室射血分数(LVEF)、纽约心功能分级<III和慢性阻塞性肺疾病。
  • 亚组分析显示糖尿病患者校正后HR=0.945(P=0.7797,交互P=0.0887),≥75岁患者校正后HR=1.063(P=0.8206,交互P=0.0902),均未见显著ICD获益。

临床怎么用

  • 对于LVEF≤35%、窄QRS的缺血性心肌病或扩张型心肌病患者,一级预防ICD治疗可考虑用于降低死亡风险。
  • 对合并糖尿病或年龄≥75岁的患者,应个体化评估ICD的预期获益,充分沟通后决策。

局限性

  • 本研究为观察性对照队列,非随机分组,尽管采用多变量模型和倾向性评分校正,仍可能存在残余混杂。
  • 亚组分析中糖尿病和≥75岁患者的交互作用P值未达到统计学显著性,结果需谨慎解读。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: The EUropean Comparative Effectiveness Research to Assess the Use of Primary ProphylacTic Implantable Cardioverter-Defibrillators (EU-CERT-ICD), a prospective investigator-initiated, controlled cohort study, was conducted in 44 centres and 15 European countries. It aimed to assess current clinical effectiveness of primary prevention ICD therapy. METHODS AND RESULTS: We recruited 2327 patients with ischaemic cardiomyopathy (ICM) or dilated cardiomyopathy (DCM) and guideline indications for prophylactic ICD implantation. Primary endpoint was all-cause mortality. Clinical characteristics, medications, resting, and 12-lead Holter electrocardiograms (ECGs) were documented at enrolment baseline. Baseline and follow-up (FU) data from 2247 patients were analysable, 1516 patients before first ICD implantation (ICD group) and 731 patients without ICD serving as controls. Multivariable models and propensity scoring for adjustment were used to compare the two groups for mortality. During mean FU of 2.4 ± 1.1 years, 342 deaths occurred (6.3%/years annualized mortality, 5.6%/years in the ICD group vs. 9.2%/years in controls), favouring ICD treatment [unadjusted hazard ratio (HR) 0.682, 95% confidence interval (CI) 0.537-0.865, P = 0.0016]. Multivariable mortality predictors included age, left ventricular ejection fraction (LVEF), New York Heart Association class <III, and chronic obstructive pulmonary disease. Adjusted mortality associated with ICD vs. control was 27% lower (HR 0.731, 95% CI 0.569-0.938, P = 0.0140). Subgroup analyses indicated no ICD benefit in diabetics (adjusted HR = 0.945, P = 0.7797, P for interaction = 0.0887) or those aged ≥75 years (adjusted HR 1.063, P = 0.8206, P for interaction = 0.0902). CONCLUSION: In contemporary ICM/DCM patients (LVEF ≤35%, narrow QRS), primary prophylactic ICD treatment was associated with a 27% lower mortality after adjustment. There appear to be patients with less survival advantage, such as older patients or diabetics.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Zabel M, Willems R, Lubinski A, et al. Clinical effectiveness of primary prevention implantable cardioverter-defibrillators: results of the EU-CERT-ICD controlled multicentre cohort study. Eur Heart J. 2020. PMID: 32372094. doi:10.1093/eurheartj/ehaa226

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。